The U.S. Food and Drug Administration has finalized its guidance for psychedelic clinical trials — the rulebook researchers must follow when studying substances like psilocybin, LSD and MDMA as medicines. Published on July 14, 2026, the final guidance replaces the 2023 draft, and the agency paired it with something arguably bigger: a public hearing on September 14, 2026, about how psychedelic therapy should actually work in practice — including who should be allowed to guide it.
What the FDA actually published
The document is titled “Psychedelic Drugs: Considerations for Clinical Investigations,” and its purpose is to help researchers navigate what the FDA itself calls the “unique challenges” of studying psychedelics. Both the guidance and the hearing announcement appeared in the Federal Register on July 14, 2026, first reported by Tom Angell at Marijuana Moment.
The central problem the guidance wrestles with is one every ceremony participant understands intuitively: you know when you’ve taken a psychedelic. In trial language, this is “functional unblinding” — the perceptual shifts reveal who received the active substance, inviting expectation bias. The final guidance treats this as a design challenge to be mitigated, not a disqualifying flaw.
The key changes at a glance
| Area | What the final guidance says |
|---|---|
| Blinding | Functional unblinding must be addressed in trial design; expectation bias acknowledged as a core obstacle |
| Safety | Two trained monitors should oversee each administration session |
| Abuse potential | Risk-based approach; computational models may replace some new animal studies for well-characterized substances — a loosening compared to the 2023 draft |
| Durability | Sponsors must demonstrate long-term effects, not assume them from a few doses |
| Public hearing | September 14, 2026 (hybrid, FDA White Oak campus): provider training and credentialing, patient safety, access, data standards |
According to Clinical Trials Arena’s analysis, the abuse-potential shift is the most concrete change from the draft. The move follows a 2026 executive order directing federal agencies to speed up psychedelic research.
Why the September hearing matters more than the guidance
The hearing is where regulation touches practice. The FDA wants feedback on provider training and credentialing, patient safety in “supervised and supportive settings,” access, and standardized data collection. Oral-comment registration closes August 21, 2026; written comments are open until October 5, 2026. Notably, the agency has drawn a firm line around scope: it will not take comments on rescheduling, legalization, or religious and personal use.
What this means for practitioners
For those of us working in shamanic and spiritual traditions, the guidance itself changes nothing about our daily work — I don’t use psychedelics in my practice, and shamanic journeying with the drum has never needed them. But I’d be careless to pretend this news doesn’t concern us. The question the FDA has now put on the official agenda — who is qualified to hold space for someone in a non-ordinary state of consciousness — is the question our field has been circling for decades.
Two things stand out to me. First, the two-monitor requirement is a quiet acknowledgment that set and setting are not decoration; they are the safety architecture. Traditional lineages have always known this — the ceremony holder, the helpers, the container. It is striking to watch a regulator arrive at the same conclusion through adverse-event data. Second, the credentialing conversation will not stay inside clinics. Whatever standards emerge in September will shape what clients expect from anyone guiding altered states — including retreat leaders and shamanic practitioners who never touch a medicine. The bar for transparency about training is rising, and I think that’s healthy.
There is also a gap worth naming: the FDA explicitly excluded religious and traditional use from the hearing. Indigenous communities whose knowledge underpins this field are once again outside the room where the rules are written. The written-comment docket, though, is open to anyone — including voices from outside the clinical world.
If you’re exploring this territory personally, start with the fundamentals: understand what happens in a shamanic healing session, learn how to vet a retreat and its facilitators, and know that the deeper skills are learnable — here’s my honest answer on whether anyone can learn shamanism.
Frequently asked questions
Did the FDA approve psychedelic therapy?
No. The FDA finalized guidance on how clinical trials of psychedelics should be designed and run. No psychedelic-assisted therapy has been approved through this pathway yet.
What happens at the September 14, 2026 hearing?
The FDA will gather public feedback on the therapeutic use of psychedelics in supervised settings — provider training and credentialing, patient safety, access, and data collection. It runs 12:30–4:30 p.m. ET as a hybrid event at the FDA’s White Oak campus and online.
Does this affect traditional or ceremonial use of plant medicines?
Not directly. The guidance covers clinical research only, and the FDA explicitly excluded religious, traditional and personal use from the hearing’s scope. Legal frameworks for ceremonial use remain a separate — and largely unresolved — question.
Can members of the public submit comments?
Yes. Anyone can submit written comments to the FDA docket until October 5, 2026. Requests to speak at the hearing itself must be registered by August 21, 2026.
This article reports on regulatory news and is for informational purposes only. It is not medical advice. Psychedelic substances remain controlled substances in most jurisdictions, and decisions about mental health treatment belong in conversation with qualified medical professionals.
Sources: FDA, “Psychedelic Drugs: Considerations for Clinical Investigations” (final guidance, July 2026); FDA public hearing notice, September 14, 2026; Marijuana Moment (Tom Angell, July 13, 2026); Clinical Trials Arena (July 14, 2026).
